Literature DB >> 15372603

Cigarette smoking in Parkinson's disease: influence on disease progression.

Guido Alves1, Martin Kurz, Stein A Lie, Jan P Larsen.   

Abstract

Previous studies have shown an inverse association between smoking and the prevalence of Parkinson's disease (PD), suggesting that smoking may induce a biological protection against nigral neuronal damage. In 1993, we examined the frequency of cigarette smokers among 239 patients with PD and two control groups. In addition, the progression of parkinsonism and other clinical features were followed prospectively in smoking and nonsmoking PD patients over an 8-year period. Mortality in the two PD groups was also examined. We found a 50% higher prevalence of smokers in the control groups than in patients with PD. In contrast, during the follow-up period, there were no significant differences in progression of parkinsonism, cognitive impairment, and mood in smoking and nonsmoking patients with PD. Mortality was also similar in the two groups. The lack of influence on disease progression may indicate that cigarette smoking does not have a major neuroprotective effect in patients with already diagnosed PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15372603     DOI: 10.1002/mds.20117

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

Review 3.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 4.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 5.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

6.  Mortality and Its Risk Factors in Patients with Rapid Eye Movement Sleep Behavior Disorder.

Authors:  Junying Zhou; Jihui Zhang; Siu Ping Lam; Vincent Mok; Anne Chan; Shirley Xin Li; Yaping Liu; Xiangdong Tang; Wing Ho Yung; Yun Kwok Wing
Journal:  Sleep       Date:  2016-08-01       Impact factor: 5.849

7.  The association between lifestyle factors and Parkinson's disease progression and mortality.

Authors:  Kimberly C Paul; Yu-Hsuan Chuang; I-Fan Shih; Adrienne Keener; Yvette Bordelon; Jeff M Bronstein; Beate Ritz
Journal:  Mov Disord       Date:  2019-01       Impact factor: 10.338

8.  Smoking cessation for the neurologic patient.

Authors:  Jinny Tavee
Journal:  Neurol Clin Pract       Date:  2012-06

9.  Smoking duration, intensity, and risk of Parkinson disease.

Authors:  H Chen; X Huang; X Guo; R B Mailman; Y Park; F Kamel; D M Umbach; Q Xu; A Hollenbeck; A Schatzkin; A Blair
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

10.  Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.

Authors:  Amandeep Mann; Sharon Miksys; Anna Lee; Deborah C Mash; Rachel F Tyndale
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.